NASDAQ:KRRO Korro Bio Q4 2024 Earnings Report $13.28 -0.01 (-0.08%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$13.30 +0.03 (+0.19%) As of 08/14/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Korro Bio EPS ResultsActual EPS-$2.26Consensus EPS -$2.33Beat/MissBeat by +$0.07One Year Ago EPSN/AKorro Bio Revenue ResultsActual Revenue$2.27 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKorro Bio Announcement DetailsQuarterQ4 2024Date3/18/2025TimeBefore Market OpensConference Call DateTuesday, March 18, 2025Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Korro Bio Earnings HeadlinesKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 14 at 4:05 PM | globenewswire.comWhat is HC Wainwright's Forecast for Korro Bio Q3 Earnings?August 13 at 1:43 AM | americanbankingnews.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Halozyme (HALO) and Resmed (RMD)August 12, 2026 | theglobeandmail.comWall Street Zen Upgrades Korro Bio (NASDAQ:KRRO) to SellAugust 8, 2026 | americanbankingnews.comKorro Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 6, 2026 | globenewswire.comSee More Korro Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Korro Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Korro Bio and other key companies, straight to your email. Email Address About Korro BioKorro Bio (NASDAQ:KRRO) is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases. The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics. Lead candidate KB103 is an investigational enzyme replacement therapy designed to address congenital hyperbilirubinemia by restoring deficient UGT1A1 activity. In parallel, Korro Bio is advancing a portfolio of live microbial drug candidates aimed at modulating the human microbiome to treat unmet medical needs in gastroenterology and oncology. These programs reflect the company’s dual focus on systemic enzyme therapies and targeted microbial approaches. Founded in 2019 and headquartered in Boston, Massachusetts, Korro Bio completed its initial public offering on the Nasdaq under the ticker KRRO in late 2021. The company collaborates with leading academic and industry partners to expand its enzyme discovery platform and accelerate translational research. Led by an experienced management team with backgrounds in biotherapeutics, protein science and drug development, Korro Bio serves a global pharmaceutical customer base and is committed to advancing innovative treatments from bench to bedside.View Korro Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsBack From Orbit, Intuitive Machines' Share Price Enters the Buy ZoneCerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More Divided Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
